Curve Therapeutics

British science is often held up as a shining light: both a source of national pride thanks to the country’s huge contributions in the past, and a crucial part of the economy which should help drive g

The year 2025 is set top be a pivotal one for the biopharma industry, marked by significant political changes in the US and beyond. Around half the world’s population live in countries that held natio

FogPharma ended 2022 with a big cash haul – $178m from a series D venture capital round – and in 2023 achieved a couple of big milestones that helped the company raise its next big financing this yea

Curve Therapeutics could receive up to $1.7bn after clinching an impressive partnership deal with MSD based on its novel Microcycle technology just a few years after modest seed funding of $6.1m. To